A comprehensive resource for heart and vascular services.

  • Increase/Decrease Text Size
  • Print This Page
Back to Results Back to Search

Robert S. Gaston, M.D.

Professor

Endowed Professor of Transplant Nephrology

Interim Director, Division of Nephrology

Co-Director, Comprehensive Transplant Institute

  • Specialty
  • Sub - Specialty
    • Transplantation Surgery
    • Nephrology
  • Phone
    • (205) 934-9999
    • 1-800-UAB-8816
  • Primary Clinic Location
  • Hospital Affiliation

    UAB Hospital

  • Print this profile

Credentials

Education and Training
  • Medical School
    • St. Louis University School
    • 1979
  • Internship
    • University of Arkansas for Medical Services
    • 1980
  • Residency
    • University of Arkansas for Medical Services
    • 1982
  • Fellowship
    • University of Arkansas for Medical Services, Nephrology
    • 1986
    • University of Alabama at Birmingham, Transplantation
    • 1988
Certifications
  • American Board of Internal Medicine - Medicine 1982
  • American Board of Internal Medicine - Nephrology 1986
Memberships
  • The Transplantation Society
  • American Society of Transplantation
  • American Society of Transplant Surgeons
  • American Society of Nephrology

Clinic Information

Locations and Directions
UAB Hospital
1802 6th Avenue South
Birmingham, AL 35233

Clinical Interests

Clinical Interests

Organ transplantation; renal transplantation and the role of cytokines in transplantation.


Publications

Publications
  • Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, and Curtis JJ. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney International 39: 141-148, 1991.
  • Gaston RS, Julian BA, Diethelm AG, and Curtis JJ. Effects of enalapril on erythrocytosis after renal transplantation. Annals of Internal Medicine 115: 954-955, 1991.
  • Gaston RS, Ayres I, Dooley LG, Diethelm AG. Racial equity in renal transplantation: the disparate impact of HLA-based allocation. Journal of the American Medical Association 270: 1352-1356, 1993.
  • Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J for the Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338: 161-165, 1998.
  • Dooley LG and Gaston RS. Stumbling toward equity: the role of government in kidney transplantation. University of Illinois Law Review 1998(3): 703-725, 1999.
  • Gaston RS. Immunosuppressive Therapy. Part 1: The scientific basis and clinical practice of immunosuppressive therapy in the management of transplant recipients. In Extending Medicare Coverage for Preventive and Other Services. Field MJ, Lawrence RL, Zwanziger L, Eds. Washington, National Academy Press, 2000. pp 286-309.
  • Gaston RS. Immunosuppressive Therapy. Part 2: Evolution of Medicare policy involving transplantation and immunosuppressive medications: past developments and future directions. In Extending Medicare Coverage for Preventive and Other Services. Field MJ, Lawrence RL, Zwanziger L, Eds. Washington, National Academy Press, 2000. pp 310-328.
  • Young CJ and Gaston RS. Renal transplantation in black Americans. N Engl J Med 343: 1545-1552, 2000.
  • Gaston RS, Danovitch GM, Adams PL, Wynn JJ, Merion RM, Deierhoi MH, et al. The Report of a National Conference on the Wait List for Kidney Transplantation. Am J Transplant 3: 775-785, 2003.
  • Gaston RS, Cosio FG, Davis CL, Basadonna G, Kasiske BL, Larsen J, Leichtman AB, Delmonico FL. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis 44: 529-542, 2004.
  • Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffry J, Rush D. Long-term deterioration of kidney allograft function. Am J Transplant 5: 1405-1414, 2005.
  • Gaston RS, Danovitch GM, Epstein RA, Kahn JP, Matas AJ, Schnitzler MA. Limiting financial disincentives in live organ donation: a rational solution to the kidney shortage. Am J Transplant 6: 2548-2555, 2006.
  • Abecassis M, Bartlett SA, Collins AJ, Davis CL, Delmonico FL, Eggers P, Friedewald J, Hays R, Howard A, Jones E, Leichtman AB, Merion R, Metzger RA, Pradel F, Schweitzer EJ, Velez RL, Gaston RS. Kidney transplantation as primary therapy for ESRD: proceedings of a NKF/KDOQI conference.
  • Gaston RS, Kaplan B, Shah T, Cibrik D, Angelis M, Mulgaonkar S, Meier-Kriesche H, Patel D, Bloom R. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplantation, 9: 1607-1619, 2009.
  • Gaston RS, Cecka JM, Kasiske BL, Fiebert AM, Leduc R, Cosio FC, Gourshankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90: 68-74, 2010.
  • Lee BT, Kumar V, Williams TA, Abdi R, Bernhardy A, Dyer C, Conte S, Genovese G, Ross MD, Friedman DJ, Gaston R, Milford E, Pollak MR, Chandraker A. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 12: 1924-28, 2012.
  • Kasiske BL, McBride, MA, Cornell DL, Gaston RS, Henry ML, Irwin FD, Israni AK, Metzler NW, Murphy KW, Reed AI, Roberts JP, Salkowski N, Snyder JJ, Sweet SC. Report of a consensus conference on transplant program quality and surveillance. Am J Transplant 12: 1988-1996, 2012.

Research

Research Interests
  • Pathogenesis of chronic graft dysfunction after kidney transplantation
  • Clinical immunosuppression after kidney transplantation
  • Minority access and outcomes in kidney transplantation

Attention UAB Physicians

If you are a physician on the UAB medical staff and would like to modify your profile, please e-mail your changes to the program administrator

Update Profile
top